TICKERNERD
Menu
AKBAAKBAHealthcare · Drug Manufacturers - Specialty & Generic

AKBA Stock Forecast: Akebia Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 28 Oct 2026
$0.76
+15.85% on the day

The 6 Wall Street analysts covering Akebia Therapeutics, Inc. hold a median 12-month price target of $4 — +423.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 76 of 100 as at 27 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$182.9M
Ticker Nerd rank
76/ 100
Median analyst target
$4.00
Analysts covering
6
Revenue$49.1M−21.4% y/y
Operating income−$4.4M
Net income−$8.9M
Free cash flow−$554K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+30.7%
1M
−14.4%
YTD
−52.5%
1Y
−75.3%
From 52W high
−75.3%
From 52W low
+36.0%
$0.56
$3.09
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AKBA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Akebia Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 27 Oct 2026
76/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
96
Quality
87
Accruals
82
Size
68
Revisions
68
Growth
65
Issuance
36
Volatility
27
Momentum
9

Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (9): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

AKBA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AKBA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00$6.00Jan 26Apr 26Jul 26Oct 26AKBAHigh $6.00Median $4.00Low $1.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
5 Buy1 Hold0 Sell
Low $1.00Median $4.00High $6.00

The green dot is the last close — the median target sits +423.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 Sept 2026BTIGReiteratesBuy$4.00
8 Sept 2026WestPark CapitalInitiatesBuy$4.50
8 Aug 2026Leerink PartnersDowngradeMarket Perform—
7 Aug 2026Leerink PartnersDowngradeMarket Perform$1.00
1 July 2026HC Wainwright & Co.ReiteratesBuy$6.00
1 July 2026HC Wainwright & Co.ReiteratesBuy—
7 Apr 2026BTIGReiteratesBuy—
25 Feb 2026BTIGMaintainsBuy—
6 Feb 2026HC Wainwright & Co.ReiteratesBuy—
6 Feb 2026Piper SandlerMaintainsOverweight—
2 Dec 2025BTIGReiteratesBuy—
2 Dec 2025HC Wainwright & Co.ReiteratesBuy—
30 Oct 2025HC Wainwright & Co.MaintainsBuy—
29 Oct 2025BTIGMaintainsBuy—
4 June 2025HC Wainwright & Co.AssumesBuy$8.00
28 Apr 2025Leerink PartnersInitiatesOutperform—
4 Apr 2025HC Wainwright & Co.ReiteratesBuy—
1 Apr 2025JefferiesInitiatesBuy—
14 Mar 2025HC Wainwright & Co.ReiteratesBuy—
14 Mar 2025Piper SandlerMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

AKBA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

AKBA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 28 Oct 2026, Akebia Therapeutics, Inc. returned −75.3% against +13.6% for the S&P 500, dividends included.

AKBA vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26AKBAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AKBA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Akebia Therapeutics, Inc. (AKBA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−34.9×

Cheaper than 97% of US stocks

Price / sales
0.8×

Cheaper than 74% of US stocks

Price / book
7.2×

Cheaper than 15% of US stocks

EV / EBITDA
−52.8×

Cheaper than 94% of US stocks

Growth & margins
Revenue growth (YoY)
−21.4%

Higher than 11% of US stocks

Earnings growth (YoY)
−21.4%

Higher than 20% of US stocks

Gross margin
78.8%

Higher than 90% of US stocks

Operating margin
−5.5%

Higher than 27% of US stocks

Net margin
−13.5%

Higher than 18% of US stocks

Returns & dividend
Return on equity
−109.4%

Higher than 12% of US stocks

Return on assets
−1.1%

Higher than 39% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Akebia Therapeutics, Inc. (AKBA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Akebia Therapeutics, Inc. has a market value of $182.9M and an enterprise value of $226.6M.

  • Revenue in the twelve months to 30 June 2026: $219.1M. The latest quarter shrank 21.4% year on year.

  • Net income over the same four quarters: −$29.7M, a −13.5% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.11.

  • Free cash flow in the twelve months to 30 June 2026: $29.5M.

  • Shares outstanding: 271.7M.

  • Trailing P/E: −34.9×; forward P/E: −1.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Akebia Therapeutics, Inc. employs 194 people — $1.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

AKBA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
AKBAAkebia Therapeutics, Inc.$182.9M76
ADCTADC Therapeutics SA$197.0M81
CRDLCardiol Therapeutics, Inc.$149.2M—
SIGASIGA Technologies, Inc.$229.3M45
OGIOrganigram Global, Inc.$136.1M—
DERMJourney Medical Corp.$135.6M63
BIOABioAge Labs, Inc.$242.8M40

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Akebia Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AKBA news & analysis

U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week

GlobeNewsWire · 26 Oct 2026positive

U.S. Renal Care presented an analysis of the VOICE trial at an American Society of Nephrology Kidney Week late-breaking session, reporting a clinically meaningful safety outcome benefit for U.S. patients with anemia due to CKD on dialysis treated with vadadustat using a three-times-weekly regimen versus an ESA.

Why it matters — The reported safety findings concern vadadustat, a therapy relevant to Akebia and patients with anemia due to CKD on dialysis.

Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum

GlobeNewsWire · 7 Oct 2026neutral

Akebia Therapeutics announced that CEO John P. Butler, Chief R&D and Medical Officer Steven Burke, and Chief Financial and Chief Business Officer Erik Ostrowski will hold one-on-one meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum on October 14, 2026.

Why it matters — AKBA watchers may note the scheduled participation of senior executives in a kidney-health investor forum.

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 1 Oct 2026neutral

Akebia Therapeutics granted options to purchase 8,400 shares of common stock to one newly-hired employee on September 30, 2026, as an inducement material to the employee joining the company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — Akebia watchers may note this as a routine equity grant tied to a new hire, reflecting the company's use of stock-based incentives to attract talent.

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

GlobeNewsWire · 14 Sept 2026neutral

Akebia Therapeutics announced that the first patient has been dosed in its open-label Phase 2 basket trial evaluating ebribafusp for rare complement-mediated kidney diseases, including IgA nephropathy, lupus nephritis, and C3 glomerulopathy. Initial data from the trial is expected in 2027.

Why it matters — This marks progress in Akebia's clinical pipeline for ebribafusp, an investigational candidate in rare kidney diseases, with initial data anticipated in 2027.

FAQ

Frequently asked questions about AKBA stock

What is the AKBA stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Akebia Therapeutics, Inc. have a median 12-month price target of $4, with estimates ranging from $1 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AKBA stock a buy right now?

Of the 6 analysts covering Akebia Therapeutics, Inc., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Akebia Therapeutics, Inc. 76 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AKBA?

As at 27 Oct 2026, Akebia Therapeutics, Inc. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).

Will AKBA stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +423.1% from the last close, and Ticker Nerd's factor model ranks Akebia Therapeutics, Inc. 76 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AKBA stock forecast for 2030?

No analyst covering Akebia Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AKBA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $6 over the next 12 months.

How has AKBA stock performed over the past year?

Akebia Therapeutics, Inc. returned -75.3% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Akebia Therapeutics, Inc. do?

Akebia Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for people living with kidney disease.

What is the latest news on AKBA?

The most recent item we track (GlobeNewsWire, 26 Oct 2026): "U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week". U.S. Renal Care presented an analysis of the VOICE trial at an American Society of Nephrology Kidney Week late-breaking session, reporting a clinically meaningful safety outcome benefit for U.S. patients with anemia due to CKD on dialysis treated with vadadustat using a three-times-weekly regimen versus an ESA.

Company

About Akebia Therapeutics, Inc.

Akebia Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for people living with kidney disease. Its current product portfolio centers on treatments for chronic kidney disease-related complications, including anemia management and phosphorus control, supported by a nephrology-focused commercial organization. The company’s marketed medicines are used in renal care settings and address medical needs across dialysis and non-dialysis patient populations. Akebia also maintains a development pipeline built around hypoxia-inducible factor biology, which underpins its research in kidney disease and related metabolic disorders. Headquartered in Cambridge, Massachusetts, Akebia Therapeutics Inc. serves as a specialized player in the renal therapeutics market, combining commercial products, development-stage assets, and collaboration-based programs to support treatment options in nephrology.

CEO Mr. John P. Butler MBA · 194 employees · United States · https://www.akebia.com